Chemistry:Frespaciguat
From HandWiki
Frespaciguat (development code MK-5475) is an experimental inhaled soluble guanylate cyclase stimulator developed by Merck for pulmonary arterial hypertension.[1][2][3][4]
References
- ↑ Bajwa, Ednan K.; Cislak, Dawn; Palcza, John; Feng, Hwa-ping; Messina, Eric J.; Reynders, Tom; Denef, Jean-François; Corcea, Vasile et al. (January 2023). "Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)". Respiratory Medicine 206. doi:10.1016/j.rmed.2022.107065. PMID 36521262.
- ↑ Patel, Mahesh J.; Bajwa, Ednan K.; Cislak, Dawn; Palcza, John; Reynders, Tom; Barthson, Jenny; Lai, Eseng; Stoch, S. Aubrey (9 September 2023). "A randomized study to evaluate the effects of single-dose MK-5475 co-administered with sildenafil on systemic hemodynamics". European Respiratory Journal. doi:10.1183/13993003.congress-2023.PA1208.
- ↑ El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002. PMID 36921672.
- ↑ Tawa, Masashi; Okamura, Tomio (August 2022). "Factors influencing the soluble guanylate cyclase heme redox state in blood vessels". Vascular Pharmacology 145. doi:10.1016/j.vph.2022.107023. PMID 35718342.
 |  |
